GoodRx will restate first-half results after undercounting $29.8M in Pharma Direct revenue
GoodRx told investors not to rely on its first- and second-quarter 2026 statements. The correction raises revenue and profit, makes Pharma Direct a bigger share of sales and comes with expected material weaknesses in controls.

GoodRx's accounting error ran toward understating its business, not inflating it. The fix still means investors cannot rely on half a year of its numbers.
In a securities filing Nov. 2, GoodRx Holdings said its financial statements for the first and second quarters of 2026 should no longer be relied upon because it did not recognize part of its Pharma Direct revenue in those periods, as the ASC 606 revenue accounting standard required. The audit and risk committee of its board reached that conclusion Oct. 27, after discussions with management and the company's auditor, KPMG.
Why it matters: The correction adds $29.8 million of revenue to the first half and makes Pharma Direct, the business GoodRx has been building with drug manufacturers and other customers, a larger part of the company. As restated, Pharma Direct accounts for about 38% of second-quarter revenue, compared with about 31% as first reported. GoodRx also expects to report material weaknesses in its internal controls.
The error surfaced during an ongoing committee review of how GoodRx recognizes revenue on certain Pharma Direct transactions, according to the filing. The company said it has not found any effect on financial statements for periods before 2026.
The preliminary numbers
Under the company's preliminary figures, which it said could still change, first-quarter total revenue rises to $201.5 million from $194.0 million, with Pharma Direct revenue up $7.5 million to $59.7 million. Second-quarter total revenue rises to $222.7 million from $200.4 million, with Pharma Direct up $22.3 million to $83.9 million.
Profit rises with it. Second-quarter operating income goes to $38.5 million from $23.6 million, and net income to $19.6 million from $8.5 million. For the first half, net income rises to $24.6 million from $9.7 million, and diluted earnings per share to 7 cents from 3 cents.
When GoodRx first reported second-quarter results Aug. 5, in a release it now says should no longer be relied upon, it said revenue fell 1% from a year earlier to $200.4 million. The restated $222.7 million would be about 10% above the $203.1 million it reported for the second quarter of 2025. Restated Pharma Direct revenue of $83.9 million is about 2.4 times the $35.0 million GoodRx reported for that business a year earlier.
What the August release said
In August, GoodRx credited Pharma Direct's 76% growth to its work with drug manufacturers and other customers, especially its GLP-1 access programs. It also raised its full-year 2026 guidance at the time, to revenue of $790 million to $805 million and adjusted EBITDA of $240 million to $250 million. The Nov. 2 filing did not address that guidance.
What comes next
GoodRx said it is still assessing how the restatement affects its internal control over financial reporting and currently expects to report at least one material weakness at the close of each of the two quarters. A material weakness is a control gap serious enough that a material misstatement might not be prevented or caught in time.
The company said it is working to file amended quarterly reports for both periods "as soon as practicable." The filing did not describe the Pharma Direct transactions involved or say what changes GoodRx will make to its controls. It was signed by Wendy Barnes, chief executive and president.



